Clinical Scorecard: PsA may be linked to jaw limitations

At a Glance

Key Highlights

• Patients with PsA had higher mean JFLS-20 scores than patients without PsA (0.80 vs. 0.45); PsA remained independently associated with greater jaw limitation in adjusted analyses.
• Jaw limitation was not significantly greater in the overall psoriasis group than in healthy controls, and was concentrated among patients with PsA.
• Higher PASI scores were independently associated with poorer sleep quality; biologic treatment status was associated with better sleep quality in adjusted analyses.
• Poor sleep quality was reported by 60% of patients receiving no systemic therapy, 60% receiving nonbiologic systemic therapy, 7% receiving biologics, and 10% of controls.
• The cross-sectional design and differences in disease activity between treatment groups prevent conclusions that biologic treatment caused the observed differences.

Guideline-Based Recommendations

Diagnosis

• Jaw function was assessed with the 20-item Jaw Functional Limitation Scale (JFLS-20), covering chewing, jaw mobility, speech, and facial expression.
• Sleep quality was assessed with the Pittsburgh Sleep Quality Index (PSQI); scores greater than 5 indicated poor sleep quality.
• Cutaneous disease severity was measured using the Psoriasis Area and Severity Index (PASI).

Management

• The study did not evaluate or recommend a treatment strategy for jaw limitation or poor sleep.

Monitoring & Follow-up

• The study used patient-reported questionnaires and did not include objective dental examinations, imaging, or sleep monitoring.

Risks

• The single-center cross-sectional design, relatively small sample, and patient-reported measures limit interpretation and generalizability.
• Biologic-treated patients had lower disease activity, complicating separation of treatment-related associations from disease severity or treatment response.
• The biologic cohort excluded tumor necrosis factor inhibitors; exploratory subgroup comparisons were not adjusted for multiple testing.

Patient & Prescribing Data

The study included 178 participants: 105 patients with psoriasis (42 receiving no systemic therapy, 20 receiving conventional nonbiologic systemic therapy, and 43 receiving IL-17- or IL-23-targeting biologics) and 73 age- and sex-matched controls. Among patients with psoriasis, 26 had PsA.

Biologic-treated patients had lower mean PASI and PSQI scores than patients in the other psoriasis treatment groups. Within the PsA subgroup, biologic-treated patients had lower mean jaw limitation and PSQI scores than those not receiving biologics, but these exploratory comparisons cannot establish a treatment effect. No significant differences between IL-17/IL-17A/F and IL-23 inhibitor groups were observed for psoriasis severity, jaw limitation, or sleep quality.

Clinical Best Practices

• Interpret the reported associations as cross-sectional findings rather than evidence of causation.
• Consider PsA status when interpreting jaw functional limitation in patients with psoriasis, as PsA was independently associated with higher JFLS-20 scores in this study.
• Account for psoriasis severity and treatment-group differences when interpreting sleep-quality comparisons.

Related Resources & Content

• Skin Health and Disease study described in the supplied article